The Fort Worth Press - Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

USD -
AED 3.672504
AFN 63.503991
ALL 81.244999
AMD 376.110854
ANG 1.789731
AOA 917.000367
ARS 1399.250402
AUD 1.409443
AWG 1.8
AZN 1.70397
BAM 1.647475
BBD 2.012046
BDT 122.174957
BGN 1.647646
BHD 0.3751
BIF 2946.973845
BMD 1
BND 1.262688
BOB 6.903087
BRL 5.219404
BSD 0.998947
BTN 90.484774
BWP 13.175252
BYN 2.862991
BYR 19600
BZD 2.009097
CAD 1.36175
CDF 2255.000362
CHF 0.769502
CLF 0.021854
CLP 862.903912
CNY 6.90865
CNH 6.901015
COP 3660.44729
CRC 484.521754
CUC 1
CUP 26.5
CVE 92.882113
CZK 20.44504
DJF 177.88822
DKK 6.293504
DOP 62.233079
DZD 128.996336
EGP 46.615845
ERN 15
ETB 155.576128
EUR 0.842404
FJD 2.19355
FKP 0.733683
GBP 0.734187
GEL 2.67504
GGP 0.733683
GHS 10.993556
GIP 0.733683
GMD 73.503851
GNF 8768.057954
GTQ 7.662048
GYD 208.996336
HKD 7.81845
HNL 26.394306
HRK 6.348604
HTG 130.985975
HUF 319.430388
IDR 16832.8
ILS 3.09073
IMP 0.733683
INR 90.555504
IQD 1308.680453
IRR 42125.000158
ISK 122.170386
JEP 0.733683
JMD 156.340816
JOD 0.70904
JPY 152.72504
KES 128.812703
KGS 87.450384
KHR 4018.026366
KMF 415.00035
KPW 899.945229
KRW 1440.560383
KWD 0.30661
KYD 0.832498
KZT 494.35202
LAK 21437.897486
LBP 89457.103146
LKR 308.891042
LRD 186.25279
LSL 16.033104
LTL 2.95274
LVL 0.60489
LYD 6.298277
MAD 9.134566
MDL 16.962473
MGA 4370.130144
MKD 51.922672
MMK 2099.574581
MNT 3581.569872
MOP 8.044813
MRU 39.81384
MUR 45.903741
MVR 15.405039
MWK 1732.215811
MXN 17.164804
MYR 3.907504
MZN 63.910377
NAD 16.033104
NGN 1353.403725
NIO 36.760308
NOK 9.506104
NPR 144.775302
NZD 1.662372
OMR 0.38258
PAB 0.999031
PEN 3.351556
PGK 4.288422
PHP 57.848504
PKR 279.396706
PLN 3.54775
PYG 6551.825801
QAR 3.640736
RON 4.291404
RSD 98.909152
RUB 77.184854
RWF 1458.450912
SAR 3.749858
SBD 8.045182
SCR 13.47513
SDG 601.503676
SEK 8.922504
SGD 1.263504
SHP 0.750259
SLE 24.450371
SLL 20969.49935
SOS 570.441814
SRD 37.754038
STD 20697.981008
STN 20.637662
SVC 8.741103
SYP 11059.574895
SZL 16.029988
THB 31.080369
TJS 9.425178
TMT 3.5
TND 2.880259
TOP 2.40776
TRY 43.608504
TTD 6.780946
TWD 31.384038
TZS 2607.252664
UAH 43.08175
UGX 3536.200143
UYU 38.512404
UZS 12277.302784
VES 392.73007
VND 25970
VUV 119.325081
WST 2.701986
XAF 552.547698
XAG 0.012937
XAU 0.000198
XCD 2.70255
XCG 1.800362
XDR 0.687192
XOF 552.547698
XPF 100.459083
YER 238.350363
ZAR 15.950904
ZMK 9001.203584
ZMW 18.156088
ZWL 321.999592
  • RIO

    0.1600

    98.07

    +0.16%

  • BTI

    -1.1100

    59.5

    -1.87%

  • CMSD

    0.0647

    23.64

    +0.27%

  • BCE

    -0.1200

    25.71

    -0.47%

  • BCC

    -1.5600

    86.5

    -1.8%

  • CMSC

    0.0500

    23.75

    +0.21%

  • GSK

    0.3900

    58.93

    +0.66%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • AZN

    1.0300

    205.55

    +0.5%

  • JRI

    0.2135

    13.24

    +1.61%

  • NGG

    1.1800

    92.4

    +1.28%

  • BP

    0.4700

    37.66

    +1.25%

  • VOD

    -0.0500

    15.57

    -0.32%

  • RELX

    2.2500

    31.06

    +7.24%

  • RYCEF

    0.2300

    17.1

    +1.35%

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

ORLANDO, FLORIDA / ACCESS Newswire / October 2, 2025 / RedChip Companies will host an investor webinar with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)(NASDAQ:SXTPW), a pharmaceutical company focused on developing new medicines for vector-borne diseases, on October 22, 2025, at 4:15 p.m. ET. The event will feature 60 Degrees Pharmaceuticals' CEO Geoffrey Dow, PhD.

Text size:

Dr. Dow will highlight the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He will also outline the company's plan to expand FDA approval for tafenoquine to babesiosis-a growing tick-borne illness, incidence of which, management believes is vastly underrepresented by CDC estimates and for which there is no FDA-approved therapy. 60 Degrees Pharmaceuticals has two clinical trials (hospitalized babesiosis patients and relapsing patients) underway, and initiation of a third planned near-term.

60 Degrees Pharmaceuticals has Orphan Drug status for tafenoquine for babesiosis and patent exclusivity for the malaria indication through 2035.

A live Q&A session with management will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/SXTP/88177419350

Questions can be pre-submitted to [email protected] or online during the live event.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of vector-borne diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of War and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-REDCHIP (733-2447)
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

T.Gilbert--TFWP